Aurobindo Pharma has announced the incorporation of a new wholly owned subsidiary in Indonesia, according to reports from Business Standard. The company has established PT Auro Pharm Indonesia, which will operate as a stepdown subsidiary of the parent company. The announcement, disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, reveals that PT Auro Pharm Indonesia was officially incorporated on 1st July 2026, with approval from the Indonesian authorities received on 9th July 2026.
The newly incorporated entity, PT Auro Pharm Indonesia, is a wholly owned stepdown subsidiary of Aurobindo Pharma, as reported by Business Standard. This structure positions the Indonesian operations as part of the company's international expansion strategy. The establishment involves an initial subscription to the share capital amounting to IDR 20,000,000,000, divided into 2000 equity shares of IDR 10,000,000 each, funded entirely through cash. As a wholly-owned subsidiary, the new entity will enable Aurobindo Pharma to establish a more robust presence in Indonesia, enhancing its manufacturing capabilities and market reach within the region.
The primary objective of incorporating PT Auro Pharm Indonesia is to undertake manufacturing operations in Indonesia, according to the company announcement reported by Business Standard. This strategic move represents Aurobindo Pharma's commitment to expanding its manufacturing footprint in the Southeast Asian market. By venturing into Indonesia, Aurobindo Pharma aims to leverage its expertise in pharmaceuticals, potentially opening new avenues for growth in manufacturing and distribution channels across Southeast Asia. The company's expansion strategy underscores its commitment to enhancing its operational footprint and tapping into emerging markets.
The new subsidiary, PT Aurogen Pharma Indonesia, is described as a wholly owned stepdown subsidiary of Aurobindo Pharma, as reported by Business Standard. This corporate structure allows for a tiered ownership arrangement within the company's international operations framework. According to the disclosure, PT Auro Pharm Indonesia is a related party of Aurobindo due to its status as a wholly-owned step-down subsidiary. Notably, no governmental or regulatory approvals were needed to establish this subsidiary, streamlining the process and allowing Aurobindo Pharma to move swiftly with its plans in Indonesia.
